{"prompt": "['Product: MK-3475', '70', 'Protocol/Amendment No.: 604-09', '7. After the Safety Follow-up Visit, record all medications taken during the 14 days prior to an SAE and all medications taken to treat an SAE as defined in Section 7.2. All', 'non-study antineoplastic treatments should be documented.', '8.', 'See Section 7.2.3.1 for details on reporting timeframe for SAEs.', '9.', 'Laboratory tests for determining eligibility for retreatment are to be performed within 10 days prior to the first dose of pembrolizumab. Starting with Cycle 1 Day 1,', 'laboratory', 'safety tests must be conducted within 72 hours prior to first dose of trial treatment in each cycle, with the exception of the thyroid function tests and LDH which', 'may be conducted up to 10 days prior to first dose of trial treatment. Laboratory results, with the exception of thyroid function tests and LDH,', 'must', 'be', 'known', 'prior', 'to', 'dosing.', '10. Urinalysis is to be performed every 6 cycles.', '11. Thyroid tests are to be repeated every 2 cycles beginning at Cycle 2.', '12. For women of reproductive potential, a urine pregnancy test should be performed within 72 hours prior to first dose of trial treatment. A serum test can be considered if urine', 'is not appropriate. Monthly pregnancy testing should be conducted as per local regulations where applicable.', '13. CT with contrast (preferred) of the chest, abdomen and pelvis is required for all subjects; non-contrast CT of the chest and MRI of the abdomen and pelvis may be used for', 'subjects in whom iodinated contrast is contraindicated.', '14. Tumor imaging to be performed within 28 days prior to restarting treatment with pembrolizumab. Tumor response assessment is required every 6 weeks (42 [+ 7] days) for', 'the first 26 weeks of the Second Course Phase, then every 9 weeks (63 [I 7] days) until the subject starts a non-study cancer therapy. Refer to site imaging manual for', 'additional details. Additional imaging at Discontinuation Visit and Safety Follow-up Visit is not required provided that previous imaging assessments have been performed', 'per schedule. Additional imaging after study drug discontinuation is not required for subjects who start a non-study cancer therapy. Refer to Section 7.1.2.7 for additional', 'details.', '15. MRI (strongly preferred) or CT with contrast of the brain at baseline for all subjects. For subjects without brain metastases at diagnosis, brain imaging is required as', 'clinically indicated. For subjects with brain metastases at diagnosis that have undergone treatment, repeat brain imaging is to be performed at all post-baseline imaging', 'assessments.', '16. Nuclear medicine bone scan for all subjects, at baseline, to assess for bone lesions. Bone scan is to be repeated in subjects with bone lesions at baseline who achieve a', 'radiographic CR (to confirm osseous response) and as clinically indicated.', '17. Pembrolizumab can be administered for up to 17 cycles.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '71', 'Protocol/Amendment No.: 604-09', '7.0', 'TRIAL PROCEDURES', '7.1', 'Trial Procedures', 'The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each', 'visit. Individual trial procedures are described in detail below. It may be necessary to', 'perform these procedures at unscheduled time points if deemed clinically necessary by the', 'investigator.', 'Furthermore, additional evaluations/testing may be deemed necessary by the investigator and', 'or the Sponsor for reasons related to subject safety. In some cases, such evaluation/testing', 'may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations', 'may require that additional informed consent be obtained from the subject. In these cases,', 'such evaluations/testing will be performed in accordance with those regulations.', '7.1.1 Administrative Procedures', '7.1.1.1 Informed Consent', 'The investigator or qualified designee must obtain documented consent from each potential', \"subject or each subject's legally acceptable representative prior to participating in a clinical\", \"trial or Future Biomedical Research. If there are changes to the subject's status during the\", 'trial (e.g., health or age of majority requirements), the investigator or qualified designee must', 'ensure the appropriate consent is in place.', '7.1.1.1.1 General Informed Consent', \"Consent must be documented by the subject's dated signature or by the subject's legally\", \"acceptable representative's dated signature on a consent form along with the dated signature\", 'of the person conducting the consent discussion.', 'A copy of the signed and dated consent form should be given to the subject before', 'participation in the trial.', 'The initial informed consent form, any subsequent revised written informed consent form', \"and any written information provided to the subject must receive the IRB/ERC's\", 'approval/favorable opinion in advance of use. The subject or his/her legally acceptable', 'representative should be informed in a timely manner if new information becomes available', \"that may be relevant to the subject's willingness to continue participation in the trial. The\", 'communication of this information will be provided and documented via a revised consent', \"form or addendum to the original consent form that captures the subject's dated signature or\", \"by the subject's legally acceptable representative's dated signature.\", 'Specifics about a trial and the trial population will be added to the consent form template at', 'the protocol level.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}